Ask AI
ProCE Banner Activity

The Next Chapter in CSU: How Novel Targeted Therapies Are Transforming Practice 

Clinical Thought

Learn what limitations patients with chronic spontaneous urticaria (CSU) often face and how novel targeted therapies are transforming patient care by allowing a more personalized approach to CSU treatment.

Released: March 11, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for allergy/immunology and dermatology healthcare professionals, including physicians, residents, fellows, nurse practitioners, and physician associates, and others who care for patients with CSU.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify key cellular and molecular mechanisms involved in the pathophysiology of CSU 

  • Design evidence-based diagnostic and assessment plans for all patients with CSU

  • Evaluate recent clinical data on available and emerging therapies for patients with CSU

Disclosure

Primary Author

Daniel Butler, MD: consultant/advisor/speaker: Galderma, Leo, Sanofi; researcher: AbbVie, Incyte, Pfizer.